



## NHS MEDICAL POLICY

### Casirivimab and Imdevimab for COVID -19 + Patients Medicine 2021-001

#### A. May be indicated when ALL the following are present:

1	Administered together for the treatment of mild to moderate COVID-19 patients
2	Given to Adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds])
3	Positive results of direct SARS-Co-V-2 viral testing and who are at high risk for progressing to severe COVID-19.
4	<p>Must have at least one of the following co-morbidities:</p> <ul style="list-style-type: none"> <li>• Cancer</li> <li>• Chronic kidney disease</li> <li>• Chronic lung disease (COPD, asthma [moderate to severe]. Interstitial lung disease, cystic fibrosis, and pulmonary hypertension)</li> <li>• Dementia or other neurological condition</li> <li>• Diabetes (type 1 or type 2)</li> <li>• Down syndrome</li> <li>• Heart conditions (such as heart failure, coronary artery disease, cardiomyopathies, or hypertension)</li> <li>• HIV infection</li> <li>• Immunocompromised state</li> <li>• Liver disease such as alcohol-related liver disease, nonalcoholic fatty liver disease and cirrhosis</li> <li>• Overweight and obesity (BMI &gt;25)</li> <li>• Pregnancy and recently pregnant people (for at least 42 days following end of pregnancy)</li> <li>• Sickle cell disease or thalassemia</li> <li>• Smoking, current or former</li> <li>• Solid organ or blood stem cell transplant</li> <li>• Stroke or cerebrovascular disease</li> <li>• Substance abuse disorders</li> </ul>
5	Not hospitalized due to COVID-19

6	Does not require oxygen
---	-------------------------

**SOURCES**

U. S. Food and Drug Administration Emergency Use Authorization

**CODE REFERENCE: (This may not be a comprehensive list of codes to apply to this policy.)**

Q0243, Q0244, M0243, M0244

**POLICY HISTORY/REVISION INFORMATION**

Date	Action/Description
09/19/2022	Annual review and approval by UM Committee
08/23/2023	Annual review and approval by UM/QM Committee